No Data
No Data
Quince Therapeutics Doses First Subject in Ataxia-Telangiectasia Trial
Express News | Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA
Express News | Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Express News | Quince Expects Phase 3 Neat Results H2 2025
Express News | Quince Therapeutics Initiates Phase 3 Trial of Erydex
Express News | Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia
No Data